Reduced expression of SMARCB1/INI1 protein in synovial sarcoma

Modern Pathology

Volumn 23, Issue 7, 2010, Pages 981-990

  Kohashi, Kenichi ^a   Oda, Yoshinao ^a   Yamamoto, Hidetaka ^a   Tamiya, Sadafumi ^a   Matono, Hiroshi ^a   Iwamoto, Yukihide ^a   Taguchi, Tomoaki ^a   Tsuneyoshi, Masazumi ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA SANNO HOSPITAL   (Japan)

Author keywords

chromatin remodeling; malignant rhabdoid tumor; SMARCB1 INI1; SS18 SSX; synovial sarcoma

Indexed keywords

MESSENGER RNA; PROTEIN INI1; PROTEIN SMARCB1; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; NONHISTONE PROTEIN; SMARCB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DERMATOFIBROSARCOMA PROTUBERANS; FEMALE; FIBROSARCOMA; FUSION GENE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NERVE SHEATH TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; SYNOVIAL SARCOMA; BIOSYNTHESIS; METABOLISM; MORTALITY; PATHOLOGY; SOFT TISSUE TUMOR; SURVIVAL; WESTERN BLOTTING;

BLOTTING, WESTERN; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARCOMA, SYNOVIAL; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954228176     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.71     Document Type: Article

References (34)

1. Fisher C, de Bruijn DRH, van Kessel AG. Synovial sarcoma. In: Fletcher CDM, Unni KK, Mertens F (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press: Lyon, France, 2002, pp 200-204.
2. Oda Y, Ohishi Y, Saito T, et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol 2003;199: 251-258.
3. Izumi T, Oda Y, Hasegawa T, et al. Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression. Am J Surg Pathol 2007;31:85-94.
4. Clark J, Rocques PJ, Crew AJ, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994;7:502-508.
5. Crew AJ, Clark J, Fisher C, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J 1995;14:2333-2340.
6. de Leeuw B, Balemans M, Weghuis DO, et al. Molecular cloning of the synovial sarcoma-specific translocation (X;18)(p11.2;q11.2) breakpoint. Hum Mol Genet 1994;3:745-749.
7. Skytting B, Nilsson G, Brodin B, et al. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst 1999;91:974-975.
8. Imbalzano AN, Jones SN. Snf5 tumor suppressor couples chromatin remodeling, checkpoint control, and chromosomal stability. Cancer Cell 2005;7: 294-295.
9. Kohashi K, Izumi T, Oda Y, et al. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol 2009;40: 349-355.
10. Kohashi K, Oda Y, Yamamoto H, et al. Highly aggressive behavior of malignant rhabdoid tumor: a special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR. J Cancer Res Clin Oncol 2007;133: 817-824.
11. Kohashi K, Oda Y, Yamamoto H, et al. SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma. Am J Surg Pathol 2008;32:1168-1174.
12. Oda Y, Tsuneyoshi M. Extrarenal rhabdoid tumors of soft tissue: clinicopathological and molecular genetic review and distinction from other soft-tissue sarcomas with rhabdoid features. Pathol Int 2006;56:287-295.
13. Bourdeaut F, Fréneaux P, Thuille B, et al. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J Pathol 2007; 211:323-330.
14. Cheng JX, Tretiakova M, Gong C, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol 2008;21:647-652.
15. Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 2009;33:542-550.
16. Hoot AC, Russo P, Judkins AR, et al. Immunohisto-chemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol 2004;28:1485-1491.
17. Sigauke E, Rakheja D, Maddox DL, et al. Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis. Mod Pathol 2006;19:717-725.
18. Tsuneyoshi M, Daimaru Y, Hashimoto H, et al. The existence of rhabdoid cells in specified soft tissue sarcomas. Histopathological, ultrastructural and im-munohistochemical evidence. Virchows Arch A Pathol Anat Histopathol 1987;411:509-514.
19. Evans HL, Shipley J. Leiomyosarcoma. In: Fletcher CDM, Unni KK, Mertens F (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press: Lyon, France, 2002, pp 131-134.
20. Fisher C, van den Berg E, Molenaar WM. Adult fibrosarcoma. In: Fletcher CDM, Unni KK, Mertens F (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press: Lyon, France, 2002, pp 100-101.
21. Guillou L, Kaneko Y. Epithelioid sarcoma. In: Fletcher CDM, Unni KK, Mertens F (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press: Lyon, France, 2002, pp 205-207.
22. Scheithauer BW, Louis DN, Humter S, et al. Malignant peripheral nerve sheath tumour (MPNST). In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). World Health Organization Classification of Tumours of the Central Nervous System. IARC Press: Lyon, France, 2007, pp 160-162.
23. Schofield D. Extrarenal rhabdoid tumour. In: Fletcher CDM, Unni KK, Mertens F (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press: Lyon, France, 2002, pp 219-220.
24. Weyers W, Mentzel T, Kasper RC, et al. Fibrohistiocytic and histiocytic tumours. In: LeBoit PE, Burg G, Weedon D, Sarasain A (eds). World Health Organization Classification of Tumours, Pathology and Genetics of Skin Tumours. IARC Press: Lyon, France, 2006, pp 254-262.
25. Jin L, Majerus J, Oliveira A, et al. Detection of fusion gene transcripts in fresh-frozen and formalin-fixed paraffin-embedded tissue sections of soft-tissue sarcomas after laser capture microdissection and RT-PCR. Diagn Mol Pathol 2003;12:224-230.
26. Donner LR, Wainwright LM, Zhang F, et al. Mutation of the INI1 gene in composite rhabdoid tumor of the endometrium. Hum Pathol 2007;38:935-939.
27. Miettinen M, Limon J, Niezabitowski A, et al. Patterns of keratin polypeptides in 110 biphasic, monophasic, and poorly differentiated synovial sarcomas. Virchows Arch 2000;437:275-283.
28. Folpe AL, Schmidt RA, Chapman D, et al. Poorly differentiated synovial sarcoma: immunohistochem-ical distinction from primitive neuroectodermal tumors and high-grade malignant peripheral nerve sheath tumors. Am J Surg Pathol 1998;22:673-682.
29. van de Rijn M, Barr FG, Xiong QB, et al. Poorly differentiated synovial sarcoma: an analysis of clinical, pathologic, and molecular genetic features. Am J Surg Pathol 1999;23:106-112.
30. de Bruijn DR, dos Santos NR, Thijssen J, et al. The synovial sarcoma associated protein SYT interacts with the acute leukemia associated protein AF10. Oncogene 2001;20:3281-3289.
31. DiMartino JF, Ayton PM, Chen EH, et al. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood 2002;99:3780-3785.
32. Eid JE, Kung AL, Scully R, et al. p300 interacts with the nuclear proto-oncoprotein SYT as part of the active control of cell adhesion. Cell 2000;102:839-848.
33. Nagai M, Tanaka S, Tsuda M, et al. Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha. Proc Natl Acad Sci USA 2001;98:3843-3848.
34. Thaete C, Brett D, Monaghan P, et al. Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus. Hum Mol Genet 1999;8:585-591.